Thrombospondin 1 and vasoactive agents indirectly alter tumor blood flow

Neoplasia

Volumn 10, Issue 8, 2008, Pages 886-896

  Isenberg, Jeff S ^a   Hyodo, Fuminori ^a   Ridnour, Lisa A ^a   Shannon, Caitlin S ^a   Wink, David A ^a   Krishna, Murali C ^a   Roberts, David D ^a,b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; CD47 ANTIGEN; CYCLIC GMP; NITRIC OXIDE; OXYGEN; THROMBOSPONDIN 1; VASOACTIVE AGENT; VASOCONSTRICTOR AGENT; VASODILATOR AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CONTROLLED STUDY; FEMALE; GENE OVEREXPRESSION; IMMUNOHISTOCHEMISTRY; LIMB PERFUSION; MELANOMA; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OXYGEN BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; SKIN CARCINOGENESIS; TUMOR BLOOD FLOW;

EID: 48249107523     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.08264     Document Type: Article

References (61)

1. Zhu X, Wu S, Dahut WL, and Parikh CR (2007). Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis 49, 186-193.
2. Zlotecki RA, Baxter LT, Boucher Y, and Jain RK (1995). Pharmacologic modification of tumor blood flow and interstitial fluid pressure in a human tumor xenograft: network analysis and mechanistic interpretation. Microvasc Res 50, 429-443.
3. Shankar A, Loizidou M, Burnstock G, and Taylor I (1999). Noradrenaline improves the tumour to normal blood flow ratio and drug delivery in a model of liver metastases. Br J Surg 86, 453-457.
4. McDonald DM and Baluk P (2005). Imaging of angiogenesis in inflamed airways and tumors: newly formed blood vessels are not alike and may be wildly abnormal: Parker B. Francis lecture. Chest 128, 602S-608S.
5. Peterson HI (1991). Modification of tumour blood flow - a review. Int J Radiat Biol 60, 201-210.
6. Mollica F, Jain RK, and Netti PA (2003). A model for temporal heterogeneities of tumor blood flow. Microvasc Res 65, 56-60.
7. Fukumura D, Yuan F, Endo M, and Jain RK (1997). Role of nitric oxide in tumor microcirculation. Blood flow, vascular permeability, and leukocyte-endothelial interactions. Am J Pathol 150, 713-725.
8. Kumagai Y, Toi M, and Inoue H (2002). Dynamism of tumour vasculature in the early phase of cancer progression: outcomes from oesophageal cancer research. Lancet Oncol 3, 604-610.
9. Jain RK (2001). Delivery of molecular and cellular medicine to solid tumors. Adv Drug Deliv Rev 46, 149-168.
10. Munn LL (2003). Aberrant vascular architecture in tumors and its importance in drug-based therapies. Drug Discov Today 8, 396-403.
11. Feldmann HJ, Molls M, and Vaupel P (1999). Blood flow and oxygenation status of human tumors. Clinical investigations. Strahlenther Onkol 175, 1-9.
12. Tozer GM, Kanthou C, and Baguley BC (2005). Disrupting tumour blood vessels. Nat Rev Cancer 5, 423-435.
13. Hinnen P and Eskens FA (2007). Vascular disrupting agents in clinical development. Br J Cancer 96, 1159-1165.
14. Ignarro LJ (2002). Nitric oxide as a unique signaling molecule in the vascular system: a historical overview. J Physiol Pharmacol 53, 503-514.
15. Isenberg JS, Ridnour LA, Perruccio EM, Espey MG, Wink DA, and Roberts DD (2005). Thrombospondin-1 inhibits endothelial cell responses to nitric oxide in a cGMP-dependent manner. Proc Natl Acad Sci USA 102, 13141-13146.
16. Ridnour LA, Thomas DD, Donzelli S, Espey MG, Roberts DD, Wink DA, and Isenberg JS (2006). The biphasic nature of nitric oxide responses in tumor biology. Antioxid Redox Signal 8, 1329-1337.
17. Fukumura D and Jain RK (1998). Role of nitric oxide in angiogenesis and microcirculation in tumors. Cancer Metastasis Rev 17, 77-89.
18. Tozer GM, Prise VE, Wilson J, Cemazar M, Shan S, Dewhirst MW, Barber PR, Vojnovic B, and Chaplin DJ (2001). Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability. Cancer Res 61, 6413-6422.
19. Meyer RE, Shan S, DeAngelo J, Dodge RK, Bonaventura J, Ong ET, and Dewhirst MW (1995). Nitric oxide synthase inhibition irreversibly decreases perfusion in the R3230Ac rat mammary adenocarcinoma. Br J Cancer 71, 1169-1174.
20. Tozer GM, Prise VE, and Chaplin DJ (1997). Inhibition of nitric oxide synthase induces a selective reduction in tumor blood flow that is reversible with L-arginine. Cancer Res 57, 948-955.
21. Yuan F, Salehi HA, Boucher Y, Vasthare US, Tuma RF, and Jain RK (1994). Vascular permeability and microcirculation of gliomas and mammary carcinomas transplanted in rat and mouse cranial windows. Cancer Res 54, 4564-4568.
22. Brizel DM, Klitzman B, Cook JM, Edwards J, Rosner G, and Dewhirst MW (1993). A comparison of tumor and normal tissue microvascular hematocrits and red cell fluxes in a rat window chamber model. Int J Radiat Oncol Biol Phys 25, 269-276.
23. de Wilt JH, Manusama ER, van Etten B, van Tiel ST, Jorna AS, Seynhaeve AL, ten Hagen TL, and Eggermont AM (2000). Nitric oxide synthase inhibition results in synergistic anti-tumour activity with melphalan and tumour necrosis factor alpha-based isolated limb perfusions. Br J Cancer 83, 1176-1182.
24. Jordan BF, Misson P, Demeure R, Baudelet C, Beghein N, and Gallez B (2000). Changes in tumor oxygenation/perfusion induced by the no donor, isosorbide dinitrate, in comparison with carbogen: monitoring by EPR and MRI. Int J Radiat Oncol Biol Phys 48, 565-570.
25. Van Buren G II, Camp ER, Yang AD, Gray MJ, Fan F, Somcio R, and Ellis LM (2006). The role of nitric oxide in mediating tumour blood flow. Expert Opin Ther Targets 10, 689-701.
26. Chaplin DJ, Hill SA, Bell KM, and Tozer GM (1998). Modification of tumor blood flow: current status and future directions. Semin Radiat Oncol 8, 151-163.
27. Lala PK and Orucevic A (1998). Role of nitric oxide in tumor progression: lessons from experimental tumors. Cancer Metastasis Rev 17, 91-106.
28. Shan SQ, Rosner GL, Braun RD, Hahn J, Pearce C, and Dewhirst MW (1997). Effects of diethylamine/nitric oxide on blood perfusion and oxygenation in the R3230Ac mammary carcinoma. Br J Cancer 76, 429-437.
29. Shinoda J and Whittle IR (2001). Nitric oxide and glioma: a target for novel therapy? Br J Neurosurg 15, 213-220.
30. Ng QS, Goh V, Milner J, Stratford MR, Folkes LK, Tozer GM, Saunders MI, and Hoskin PJ (2007). Effect of nitric-oxide synthesis on tumour blood volume and vascular activity: a phase I study. Lancet Oncol 8, 111-118.
31. Roberts DD, Isenberg JS, Ridnour LA, and Wink DA (2007). Nitric oxide and its gatekeeper thrombospondin-1 in tumor angiogenesis. Clin Cancer Res 13, 795-798.
32. Andrews JC, Walker-Andrews SC, Juni JE, Warber S, and Ensminger WD (1989). Modulation of liver tumor blood flow with hepatic arterial epinephrine: a SPECT study. Radiology 173, 645-647.
33. Good DJ, Polverini PJ, Rastinejad F, Le Beau MM, Lemons RS, Frazier WA, and Bouck NP (1990). A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc Natl Acad Sci USA 87, 6624-6628.
34. Taraboletti G, Roberts D, Liotta LA, and Giavazzi R (1990). Platelet thrombospondin modulates endothelial cell adhesion, motility, and growth: a potential angiogenesis regulatory factor. J Cell Biol 111, 765-772.
35. Lawler J and Detmar M (2004). Tumor progression: the effects of thrombospondin-1 and -2. Int J Biochem Cell Biol 36, 1038-1045.
36. Isenberg JS, Ridnour LA, Dimitry J, Frazier WA, Wink DA, and Roberts DD (2006). CD47 is necessary for inhibition of nitric oxide-stimulated vascular cell responses by thrombospondin-1. J Biol Chem 281, 26069-26080.
37. Isenberg JS, Hyodo F, Matsumoto K, Romeo MJ, Abu-Asab M, Tsokos M, Kuppusamy P, Wink DA, Krishna MC, and Roberts DD (2007). Thrombospondin-1 limits ischemic tissue survival by inhibiting nitric oxide-mediated vascular smooth muscle relaxation. Blood 109, 1945-1952.
38. Isenberg JS, Romeo MJ, Abu-Asab M, Tsokos M, Oldenborg A, Pappan L, Wink DA, Frazier WA, and Roberts DD (2007). Increasing survival of ischemic tissue by targeting CD47. Circ Res 100, 712-720.
39. Zhang X, Connolly C, Duquette M, Lawler J, and Parangi S (2007). Continuous administration of the three thrombospondin-1 type 1 repeats recombinant protein improves the potency of therapy in an orthotopic human pancreatic cancer model. Cancer Lett 247, 143-149.
40. Weinstat-Saslow DL, Zabrenetzky VS, VanHoutte K, Frazier WA, Roberts DD, and Steeg PS (1994). Transfection of thrombospondin 1 complementary DNA into a human breast carcinoma cell line reduces primary tumor growth, metastatic potential, and angiogenesis. Cancer Res 54, 6504-6511.
41. Lawler J, Miao WM, Duquette M, Bouck N, Bronson RT, and Hynes RO (2001). Thrombospondin-1 gene expression affects survival and tumor spectrum of p53-deficient mice. Am J Pathol 159, 1949-1956.
42. Isenberg JS, Jia Y, Field L, Ridnour LA, Sparatore A, Del Soldato P, Sowers AL, Yeh GC, Moody TW, Wink DA, et al. (2007). Modulation of angiogenesis by dithiolethione-modified NSAIDs and valproic acid. Br J Pharmacol 151, 63-72.
43. Rae JM, Creighton CJ, Meck JM, Haddad BR, and Johnson MD (2007). MDA-MB-435 cells are derived from M14 melanoma cells - a loss for breast cancer, but a boon for melanoma research. Breast Cancer Res Treat 104, 13-19.
44. Zabrenetzky V, Harris CC, Steeg PS, and Roberts DD (1994). Expression of the extracellular matrix molecule thrombospondin inversely correlates with malignant progression in melanoma, lung and breast carcinoma cell lines. Int J Cancer 59, 191-195.
45. Fouser L, Iruela-Arispe L, Bornstein P, and Sage EH (1991). Transcriptional activity of the alpha 1(I)-collagen promoter is correlated with the formation of capillary-like structures by endothelial cells in vitro. J Biol Chem 266, 18345-18351.
46. Michaud M and Poyet P (1994). Control of the expression of thrombospondin 1 in human breast cancer cell lines. Anticancer Res 14, 1127-1131.
47. Ordonez JL, Paraoan L, Hiscott P, Gray D, Garcia-Finana M, Grierson I, and Damato B (2005). Differential expression of angioregulatory matricellular proteins in posterior uveal melanoma. Melanoma Res 15, 495-502.
48. Bastian M, Steiner M, and Schuff-Werner P (2005). Expression of thrombospondin-1 in prostate-derived cell lines. Int J Mol Med 15, 49-56.
49. Iddings DM, Koda EA, Grewal SS, Parker R, Saha S, and Bilchik A (2007). Association of angiogenesis markers with lymph node metastasis in early colorectal cancer. Arch Surg 142, 738-744; discussion 744-745.
50. Natori Y, Moriguchi M, Fujiwara S, Takeshita I, Fukui M, Iwaki T, and Kanaide H (1992). Effects of L-NMMA and L-NNA on the selective ATP-induced enhancement of intratumoral blood flow. J Cereb Blood Flow Metab 12, 120-127.
51. Swaroop GR, Malcolm GP, Kelly PA, Ritchie I, and Whittle IR (1998). Effects of nitric oxide modulation on tumour blood flow and microvascular permeability in C6 glioma. Neuroreport 9, 2577-2581.
52. ω-nitro-L-arginine, and the haemoxygenase inhibitor, zinc protoporphyrin IX, on tumour blood flow. Int J Radiat Oncol Biol Phys 42, 849-853.
53. Andrade SP, Hart IR, and Piper PJ (1992). Inhibitors of nitric oxide synthase selectively reduce flow in tumor-associated neovasculature. Br J Pharmacol 107, 1092-1095.
54. Whittle IR, Collins F, Kelly PA, Ritchie I, and Ironside JW (1996). Nitric oxide synthase is expressed in experimental malignant glioma and influences tumour blood flow. Acta Neurochir (Wien) 138, 870-875; discussion 875-876.
55. Isenberg JS, Jia Y, Fukuyama J, Switzer CH, Wink DA, and Roberts DD (2007). Thrombospondin-1 inhibits nitric oxide signaling via CD36 by inhibiting myristic acid uptake. J Biol Chem 282, 15404-15415.
56. Tozer GM, Prise VE, Bell KM, Dennis MF, Stratford MR, and Chaplin DJ (1996). Reduced capacity of tumour blood vessels to produce endothelium-derived relaxing factor: significance for blood flow modification. Br J Cancer 74, 1955-1960.
57. Hemingway DM, Chang D, Cooke TG, and Jenkins SA (1991). The effects of vasopressin infusion on hepatic haemodynamics in an experimental model of liver metastases. Br J Cancer 64, 212-214.
58. Ackerman NB, Jacobs R, Bloom ND, and Poon TT (1988). Increased capillary flow in intrahepatic tumors due to alpha-adrenergic effects of catecholamines. Cancer 61, 1550-1554.
59. Hemingway DM, Cooke TG, Chang D, Grime SJ, and Jenkins SA (1991). The effects of intra-arterial vasoconstrictors on the distribution of a radiolabelled low molecular weight marker in an experimental model of liver tumour. Br J Cancer 63, 495-498.
60. Burton MA and Gray BN (1987). Redistribution of blood flow in experimental hepatic tumours with noradrenaline and propranolol. Br J Cancer 56, 585-588.
61. Hemingway DM, Angerson WJ, Anderson JH, Goldberg JA, McArdle CS, and Cooke TG (1992). Monitoring blood flow to colorectal liver metastases using laser Doppler flowmetry: the effect of angiotensin II. Br J Cancer 66, 958-960.